Related Experiment Video

Updated: May 18, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Are biological targets the final goal for rheumatoid arthritis therapy?

Puja Sharma1, Kamla Pathak

  • 1Department of Pharmaceutics, Rajiv Academy for Pharmacy, Uttar Pradesh, India.

Expert Opinion on Biological Therapy
|September 8, 2012
PubMed
Abstract

Insights

Rheumatoid arthritis (RA) management can improve by targeting causative factors. Novel therapies offer cellular-level treatment for disability, minimizing side effects and infection risks associated with traditional approaches.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic inflammatory joint disorder causing synovial inflammation, cytokine release, joint destruction, and disability.
  • Current treatments, including disease-modifying antirheumatic agents (DMARDs) and biological agents, often fail to halt disease progression and alleviate persistent pain.
  • There is a need to address the underlying causes of RA to improve therapeutic outcomes and minimize adverse effects.

Purpose of the Study:

  • To provide a comprehensive review of rheumatoid arthritis pathology.
  • To discuss traditional and novel biological therapies for RA.
  • To explore emerging therapeutic targets and innovative treatment strategies for RA management.

Main Methods:

  • Literature review of pathological mechanisms in rheumatoid arthritis.
  • Analysis of current and emerging therapeutic agents, including DMARDs and biologics.
  • Examination of novel therapeutic targets and treatment modalities for RA.

Main Results:

  • Traditional RA treatments may not fully control disease progression or pain.
  • Newer therapeutic strategies aim to target causative factors of RA.
  • Novel therapies focus on cellular-level interventions to reduce disability.

Conclusions:

  • Effective rheumatoid arthritis management requires addressing the disease's root causes.
  • Emerging therapies offer targeted approaches to treat RA-related disability at the cellular level.
  • These novel strategies aim to improve treatment efficacy while minimizing immune system impact, infection, and inflammation.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...